{"id":"W4405044960","doi":"10.1182/blood-2024-194581","title":"A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada); Juravinski Hospital; McGill University; Jewish General Hospital","funders":"","keywords":"Rituximab; Medicine; Internal medicine; Brentuximab vedotin; Refractory (planetary science); Oncology; Phases of clinical research; Lymphoma; Clinical trial; Hodgkin lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002541535,0.001706844,0.002291735,0.0004355174,0.0004291663,0.001184244,0.001039656,0.001303099,0.00501278],"category_scores_gemma":[0.002010725,0.0008142014,0.001458267,0.0003924333,0.001411075,0.001105311,0.0005062811,0.003167608,0.0009272291],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00126253,"about_ca_system_score_gemma":0.001756163,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008811136,"about_ca_topic_score_gemma":0.002110771,"domain_scores_codex":[0.9991522,0.0004677892,0.00004523969,0.0001534999,0.00005485375,0.0001263092],"domain_scores_gemma":[0.9984062,0.0003561638,0.000362784,0.0001621303,0.00008684516,0.0006258877],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9648647,0.01800087,0.0009502645,0.0001533903,0.0004936666,0.0000355244,0.00005307132,0.0003753501,0.003949969,0.00008550566,0.0004908438,0.01054677],"study_design_scores_gemma":[0.823335,0.1726323,0.001906524,0.00001393823,0.0003331188,0.00003930974,0.00002430136,0.0005646129,0.0005081064,0.000139057,0.0004910928,0.00001265327],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9923282,0.0009085863,0.0005635897,0.0003280189,0.0002556356,0.003868205,0.0005778042,0.00006714363,0.001102731],"genre_scores_gemma":[0.9902077,0.0007637911,0.001492729,0.0006839961,0.0003028986,0.004063286,0.0008498576,0.00002256117,0.001613134],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00501278,"threshold_uncertainty_score":0.01676941,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01381927025567285,"score_gpt":0.2782877504936997,"score_spread":0.2644684802380268,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}